Location
United States, North America
Cheque size
$100K - $5M
Investment Stage
Seed
Series A
Focus Areas
Health IT
Digital Health
BioTech
Pharmaceuticals
Medical Devices
About Investor
Mara Aspinall is a Partner at Illumina Ventures, where she focuses on genomics, diagnostics, precision health, life science tools, and therapeutics. She joined Illumina Ventures in 2023 after co-founding BlueStone Venture Partners and brings more than 30 years of leadership experience across healthcare, diagnostics, and biotechnology. Her current portfolio involvement includes Predicta Biosciences, Genome Medical, and Syntax Bio, while her earlier BlueStone investments included Paradigm Diagnostics.
Previous investments
Predicta Biosciences
5M |2024
Paradigm Diagnostics
15M |2019
Similar Investors
AL
Abdul Ly
United States, North America
$1M - $4M
Seed
,Series A
,PS
Paul Straub
United States, North America
$100K - $2M
Pre Seed
,Seed
,SA
Shaun Abrahamson
United States, North America
$250K - $1M
Pre Seed
,Seed
,RF
Riley Florsheim
United States, North America
$100K - $5M
Pre Seed
,Seed
,SB
Steve Brownlie
United States, North America
$250K - $1.4M
Pre Seed
,Seed
,DG
Danielle Graham
Canada, North America
$100K - $300K
Pre Seed
,Seed
,Is this Your Profile?
If you have any updates, please fill out our form.
